drugset / Trial / NCT02674386

Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement

NCT02674386

Phase 3 Completed 154 enrolled Pfizer Eli Lilly and Company · collab
NaSingle-groupOpen-labelOther

Summary

A4091064 is a multicenter, long-term observational study of subjects from tanezumab interventional studies (regardless of treatment group) who undergo a total knee, hip or shoulder replacement during participation in the study. The study is designed with a total duration of subject follow-up of 24 weeks after the total joint replacement surgery. There will be two methods of data collection utilized in this study: interview by site staff via the telephone and interactive web-response system (or paper if the subject has no access to the internet).

Timeline

Start
2016-08-23
Primary completion
2019-07-15
Completion
2019-07-15

Drugs

EvaluationDrugModalityDoseRoute
Background Celecoxib Other / unclassified
Background Diclofenac Other / unclassified
Background Naproxen Small molecule
Background Tanezumab Monoclonal antibody 2.5 mg
Background Tanezumab Monoclonal antibody 5 mg

Indications